Adaptimmune therapeutics plc and cryoport, inc. announce agreement to ensure safe and fully monitored transport of adaptimmune’s cell therapies

Adaptimmune therapeutics plc and cryoport, inc. announced a 3-year agreement to ensure safe and fully monitored transport of adaptimmune’s cell therapies. this agreement with cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. this agreement follows a previous relationship between both companies to support research-based shipments. in addition, cryoport has a strong partnership with adaptimmune’s preferred specialty logistics provider, further enabling seamless customer support and optimal handling of critical shipments. cryoport’s proprietary smartpak ii condition monitoring system provides near real-time information while tracking location, temperature, orientation, humidity, and shock as well as other factors to enable the transport of temperature sensitive cell therapies. this information is automatically collected and retained by cryoport’s cloud based cryoportal logistics management platform, which gives companies the ability to intervene and make corrections while a shipment is in transit.
CYRX Ratings Summary
CYRX Quant Ranking